Health Care Sector Update for 06/20/2017: JNJ, PFE, ABT, MRK, AMGN, LPCN, PRXL, MD

Shutterstock photo

Top Health Care stocks:

JNJ: flat

PFE: flat

ABT: flat

MRK: flat

AMGN: -1%

Health care shares were mostly lower in pre-market trade Tuesday.

In health care stocks news, Lipocine ( LPCN ) rose 30.1% after it reported late Monday that both the Dosing Validation and the Dosing Flexibility studies evaluating efficacy and tolerability of LPCN 1021 successfully met Food and Drug Administration primary efficacy guidelines. LPCN 1021 is an oral testosterone product candidate for testosterone replacement therapy ( TRT ) in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. In the DV study, 81% of the subjects achieved average testosterone levels within the normal range with a lower bound confidence interval of 72% . The DF study restored 70% of the subjects' average testosterone levels within the normal range confirming that twice daily dosing is the appropriate dosing regimen for LPCN 1021 and will be the basis for resubmission. The results from these studies confirm the validity of a fixed dose approach without the need for dose titration to orally administering LPCN 1021.

In other sector news,

(+) PRXL (+4.3%) Confirms deal to be bought for $88.10/share cash by Pamplona Capital

MD (flat) Buys maternal-fetal medicine practice in Tennessee

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing , US Markets
Referenced Symbols: LPCN , TRT , JNJ , PFE , ABT

More from MT Newswires


MT Newswires

MT Newswires

Market News, Commodities

Research Brokers before you trade

Want to trade FX?

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com